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2013= 608 756€ /34.09%; max2013= 2 394 665€ ; min2009= 1 785 909€ ; AVG= 2 015 533€ ; 
Mean= 1 983 142€ ; SD= 19 398). The share of MDCT on the patient supplements 
of MD slightly increased (MDCT/MD2009= 3.74%; MDCT/MD2013= 5.42%; Δ MDCT/
MD2009-2013= 1.68%). The total patient supplements increased (Δ 2009-2013= 165 
257€ /141.27%; max2013= 282 248€ ; min2009= 116 991€ ; AVG= 181 612€ ; Mean= 160 
686€ ; SD= 67 547). ConClusions: MDCT have supplements for patients that greatly 
exceed the reimbursement from the resources of public health insurance. Legislative 
changes in the list of categorized medical devices brought gradual increase patient´s 
co-payment for MDCT.
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objeCtives: Incontinence constitutes not only a serious medical problem, but 
a problem with a significant financial burden both public health insurance and 
patient. Performed analysis can serve as a base for legislative measures in the area 
of price regulation and management of their rational prescription for the benefit 
of the patient. The medical devices for patient with incontinence (MDI) are almost 
completely reimbursed from Health insurance funds respecting quantitative lim-
its. Methods: The target of the work was to analyse the data from paid data-
bases of Slovak authority National Center for Health Information that collects the 
outputs of provided health care. The data were focused on totally or partly reim-
bursed medical devices from public health insurance funds. The selected group 
was medical devices for people with diabetes (1.1. 2009 - 31.12. 2013). It was used 
basic and advanced statistic processing by Microsoft Excel. Results: Referring 
to the Center for Health Information, in the observed period, the share of MDI on 
total consumption of MD increased (MDI/MD2009= 78.50%; MDI/MD2013= 86.77%; 
Δ MDI/MD2009-2013= 8.27%). The total quantitative consumption MDI also increased 
(Δ 2009-2013= 27 186 148pcs/41.47%; max2013= 92 748 295pcs; min2009= 65 562 
147pcs; AVG= 79 331 861pcs; Mean= 79 160 957pcs; SD= 10 905 444). The share of 
MDI on total reimbursement of MD stagnated (MDI/MD2009= 30.61%; MDI/MD2013= 
30.65%; Δ MDI/MD2009-2013= 0.04%). The total reimbursement in the observed period 
increased (Δ 2009-2013= 8 468 173€ /22.19%; max2013= 47 979 262€ ; min2009= 39 266 
765€ ; AVG= 42 961 151€ ; Mean= 43 350 989€ ; SD= 3 684 081). The total patient supple-
ments also decreased (Δ 2009-2013= -4 001€ /-67.02%; max2009= 5 970€ ; min2013= 1 
969€ ; AVG= 6 475€ ; Mean= 2 125€ ; SD= 8 257). ConClusions: According to the Health 
Insurance Funds annual reports the increase of costs was due to the change in 
therapies that require the use of medical devices for long-term outpatient care, such 
are dialysis patients, or patients assigned to a kidney transplant. These patients use 
medical devices for sterile intermittent catheterization, which reduce the risk of 
infections, administration of antibiotics and subsequent hospital admission.
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objeCtives: The costs for medical devices are growing due to civilization, chronic, 
oncological diseases as well as aging of the population. Reimbursement of medi-
cal devices covers also expensive medical devices for preparation and transmis-
sion of cytostatic, vacuum therapy system and medical devices for moist wound 
healing. Methods: The target of the work was to analyze the data from paid 
databases of Slovak authority National Center for Health Information that collects 
the outputs of provided health care. The data were focused on totally or partly 
reimbursed medical devices from public health insurance funds. The selected 
group were medical devices for bandaging and plasters (MDB). The most recent 
data were from 1.1. 2009 - 31.12. 2013. It was used basic and advanced statis-
tic processing by Microsoft Excel. Results: Referring to the Center for Health 
Information, in the observed period, the share of MDB on total consumption of 
MD decreased (MDB/MD2009= 12.88%; MDB/MD2013= 6.15%; Δ MDB/MD2009-
2013= -6.73%). The total quantitative consumption MDB also decreased (Δ 2009-
2013= -4 178 456pcs/-38.86%; max2009= 10 753 703pcs; min2012= 6 575 247pcs; 
AVG= 7 281 090pcs; Mean= 6 575 247pcs; SD= 1 978 697). The share of MDB on total 
reimbursement of MD increased (MDB/MD2009= 5.86%; MDB/MD2013= 10.55%; 
Δ MDB/MD2009-2013= 4.69%). The total reimbursement in the observed period 
increased (Δ 2009-2013= 8 986 420€ /119.44%; max2013= 16 510 294€ ; min2009= 7 523 
874€ ; AVG= 12 123 793€ ; Mean= 12 841 757€ ; SD= 3 674 676). The share of MDB on the 
patient supplements of MD decreased (MDB/MD2009= 5.66%; MDB/MD2013= 3.48%; 
Δ MDB/MD2009-2013= -2.18%). The total patient supplements slightly increased 
(Δ 2009-2013= 4 435€ /2.50%; max2013= 181 607€ ; min2009= 177 172€ ; AVG= 170 335€ ; 
Mean= 168 686€ ; SD= 8 842). ConClusions: According to the Health Insurance 
Funds annual reports the increase of costs was due to the introduction of treat-
ment using moist wound healing devices. The effectiveness of it is very high, 
since moisture is important for wound, granulation and epithelialization. Another 
advantage is prolonged interval between exchanges of MD, which significantly 
increases the quality of life of treated patients.
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objeCtives: The most important factor in the increased cost of medical devices 
(MD), especially in the group medical devices for people with ostomy, is a growing 
proportion of lifestyle diseases that require long-term use of medical devices. The 
medical devices for ostomies (MDO) are almost totally reimbursed from Health 
insurance funds totally. Methods: The target of the work was to analyse the data 
patients choose breast forms of character higher functional properties that increase 
the comfort after mastectomy.
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objeCtives: Companion devices are non-invasive devices that track, log or display 
essential information related to the safe and effective use of a drug or drug delivery 
device. By monitoring a patient’s personalized health data, mHealth allows for a 
greater degree of personalized and appropriate care provision for each patient, as 
well as collecting data to support decision making. Whilst analysts expect strong 
growth for the mHealth market globally, the perceived barriers, unclear reim-
bursement guidelines and absence of established pathways for adoption have 
limited its uptake To that end, the objectives of this research were to: A. Present 
potential reimbursement and adoption pathways for companion devices B. Assess 
perceived benefits & barriers by key stakeholders for the adoption of companion 
devices. Methods: A review of the literature published since 2010 and archived in 
PubMed and Medline, and clinical practice guidelines for common chronic diseases 
such as asthma/COPD was conducted. Additionally, health technology assessments 
(HTAs) related to mHealth and remote monitoring devices across the EU5 were 
reviewed. Results: Multiple routes to market were identified for mHealth, either 
as a stand-alone device or combining a drug and device. Each route has distinct 
challenges and benefits in terms of the assessment process and demonstrating 
value to stakeholders. ConClusions: As an emerging market segment, companion 
devices are expected to play a role along the full continuum of patient care: from 
prevention, diagnosis, treatment, to monitoring. Although reimbursement for com-
panion devices varies widely across Europe and continues to be challenging, several 
distinct initiatives in local health economies are demonstrating the willingness of 
clinicians and payers to adopt the new technology. As such, this study identified 
key issues that need to be addressed
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objeCtives: Turkish medical device sector has its own unique reimbursement and 
pricing setting. Pricing of medical devices is statutorily not regulated and freely 
set by manufacturers. However, Social Security Institution (SSI), the only compe-
tent authority for reimbursement, has been monitoring which devices to reim-
burse and regulate reimbursement prices through official SSI generic positive lists 
(since 2011). Objective of this study is to describe the system used to define ceiling 
prices for reimbursement, concurrently assessing its alteration. Methods: Health 
Implementation Communiqué (SUT) and public procurement law history regarding 
medical device pricing are analyzed. Results: Our study shows that government’s 
impact has increased on reimbursement prices as a result of increasing budgetary 
concerns. After Public Procurement Law initiated in 2008, medical devices were 
sold at manufacturer defined prices and Public Procurement System (PPS) sales 
records were used to find average procurement price, which was then determined 
as reimbursement price. After SSI’s first implementation of positive lists in 2011, 
“average or lowest price in PPS” is used again to define ceiling prices, yet there were 
still items without a price. Since October 2014, the control over the reimbursement 
prices has increased as all items on SUT positive lists were assigned a price and 
no more “average price rule” of past procurement records exists. However, it is not 
clear how these reimbursement prices are defined and transparently conducted 
currently. ConClusions: Reimbursement prices are determined according to a 
merely retrospective and detection of lowest or average price practice. Effectiveness 
of this practice is the main concern since the data on PPS by hospitals may be mis-
recorded by hospitals. It has been quite challenging to develop clear and fair criteria 
for reimbursement pricing. There remains an urgent need for productive discussion 
and collaboration between government and industry regarding reasonable funding, 
transparency, and clarity in the Turkish reimbursement pricing process
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objeCtives: The main factor influencing the costs development of medical devices 
for compression therapy of venous insufficiency (MDCT) are new diagnostic and 
therapeutic possibilities, expanding the range of medical devices with new func-
tions and a subgroup compression stockings containing silver. MDCT are reim-
bursed from Health insurance funds, but there is a presence of a high patient 
co-payment. Methods: The target of the work was to analyse the data from 
paid databases of Slovak authority National Center for Health Information that 
collects the outputs of provided health care. The data were focused on totally or 
partly reimbursed medical devices (MD) from public health insurance funds. The 
selected group was medical devices for compression therapy of venous insuffi-
ciency. The most recent data were from 1.1. 2009 - 31.12. 2013. It was used basic and 
advanced statistic processing by Microsoft Excel. Results: Referring to the National 
Center for Health Information, in the observed period, the share of MDCT on total 
consumption of MD stagnated (MDCT/MD2009= 0.09%; MDCT/MD2013= 0.12%; 
Δ MDCT/MD2009-2013= 0.04%). The total quantitative consumption MDCT increased 
(Δ 2009-2013= 51 760pcs/66.72%; max2013= 129 339pcs; min2009= 77 579pcs; AVG= 98 
910pcs; Mean= 95 987pcs; SD= 19 398). The share of MDCT on total reimbursement 
of MD stagnated (MDCT/MD2009= 1.39%; MDCT/MD2013= 1.53%; Δ MDCT/MD2009-
2013= 0.14%). The total reimbursement in the observed period increased (Δ 2009-
